Slide 3
Image is not available
A platform company
Linking pharmaceutical innovation and
commercialization with strong product
lifecycle management capability
Slide 1
Image is not available
Committed to building a pharmaceutical
ecosystem focused on delivering solutions in
an open and collaborative setting for
the benefit of all stakeholders
To fulfill unmet clinical needs
Slide 2
Image is not available
Providing competitive
products and services
To enable the more effective diagnosis
and treatment, whilst enhancing clinical
practice to the ultimate benefit of the patient
previous arrow
next arrow

Innovation

Bio-technology incubation platform

Focusing on unmet clinical needs, we collaborate with global biotech/biopharma to jointly develop first- or best-in-class innovative products. 

go

INNOVATION

Business

Commercialization platform

Adhering to the patient-centered philosophy, we are dedicated to providing competitive products and services that enable the more effective diagnosis and treatment, whilst enhancing clinical practice to the ultimate benefit of the patient.

go

BUSINESS

Cardio-cerebrovascular
and gastroenterology

Dermatology
and medical aesthetic

Ophthalmology

Southeast Asia Business

News

2024-04-16

China Medical System: New Drug Application of Ruxolitinib Cream Approved in Macau

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People’s Republic of China (“Macau”) has approved the new drug application of Ruxolitinib Cream (the “Product”) on 11 April 2024. The drug registration certificate was obtained on 16 April 2024. The Product is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.   Ruxolitinib cream, a novel cream formulation of Incyte’s (NASDAQ:INCY) selective JAK1/JAK2 inhibitor ruxolitinib[1], is the first and only topical JAK inhibitor approved for use in the United States. Ruxolitinib cream is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) […]

go
战略合作&联系我们

Partnering

We collaborate with global innovative companies in flexible structures to jointly build a pharmaceutical ecosystem in a sustainable and collaborative setting for the benefit of all stakeholders.

go

Contact Us

If you are interested in joining us, or curious about our business and products, please feel free to contact us.

go